您好,欢迎来到化工原料网! [登录] [免费注册]
化工原料网
位置:首页 > 产品库 > Ammonium Glycyrrhizinate
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Ammonium Glycyrrhizinate
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Ammonium Glycyrrhizinate图片
CAS NO:53956-04-0
包装与价格:
包装价格(元)
10 mM * 1 mL in DMSO电议
500mg电议
1 g电议
5 g电议
10 g电议

产品名称
Monoammonium glycyrrhizinate
Glycyrrhizic acid ammonium salt
Ammonium Glycyrrhizate
产品介绍
Ammonium glycyrrhizinate (Monoammonium glycyrrhizinate) 具有抗炎、抗过敏、抗胃溃疡、抗肝炎等药理活性。
生物活性

Ammonium glycyrrhizinate (Monoammonium glycyrrhizinate) has various pharmacological actions such as anti-inflammatory, antiallergic, antigastriculcer, and antihepatitis activities.

体内研究
(In Vivo)

The increase of the lung W/D weight ratios is significantly reduced by high and medium dose of MAG (10 and 30mg/kg) administration. Pretreatment with MAG (10 and 30mg/kg) efficiently reduces the production of TNF-α and IL-1β. MAG (10, 30mg/kg) significantly decreases NF-κB p65 protein expression, compared with LPS. On the contrary, LPS significantly reduces IκB-α protein expression compared with the control group, whereas MAG (10 and 30mg/kg) significantly increased IκB-α expression, compared with the LPS group[1].
Low- and high-dose MAG treatment significantly reduces the AST, ALT, TBIL, and TBA levels at 14 and 21 d time points when compared with that of the RIF and INH group, suggesting the protective effect of MAG on RIF- and INH-induced liver injury. MAG treatment groups elevate the hepatic GSH level at 7, 14, and 21 d time points and markedly reduce the MDA level at 14 and 21 d time points in RIF- and INH-treated rats, suggesting the protective effect of MAG in RIF- and INH induced liver injuries[2].

Clinical Trial
分子量

839.96

性状

Solid

Formula

C42H65NO16

CAS 号

53956-04-0

结构分类
  • Terpenoids
  • Triterpenes
来源
  • Plants
  • Leguminosae
  • Glycyrrhiza uralensisFisch.
运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

-20°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

溶解性数据
In Vitro: 

DMSO : 100 mg/mL(119.05 mM;Need ultrasonic)

配制储备液
浓度溶剂体积质量1 mg5 mg10 mg
1 mM1.1905 mL5.9527 mL11.9053 mL
5 mM0.2381 mL1.1905 mL2.3811 mL
10 mM0.1191 mL0.5953 mL1.1905 mL
*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80℃, 6 months; -20℃, 1 month (sealed storage, away from moisture)。-80℃ 储存时,请在 6 个月内使用,-20℃ 储存时,请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂: 10% DMSO    40%PEG300   5%Tween-80   45% saline

    Solubility: ≥ 2.5 mg/mL (2.98 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (2.98 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠,完全溶解于 100 mL ddH2O 中,得到澄清透明的生理盐水溶液
  • 2.

    请依序添加每种溶剂: 10% DMSO    90% (20%SBE-β-CDin saline)

    Solubility: ≥ 2.5 mg/mL (2.98 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (2.98 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中,再用生理盐水定容至 10 mL,完全溶解,澄清透明
  • 3.

    请依序添加每种溶剂: 10% DMSO    90%corn oil

    Solubility: ≥ 2.5 mg/mL (2.98 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (2.98 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。

*以上所有助溶剂都可在本网站选购。